SCHEMBL16667366

SCHEMBL16667366

COCC(C)NC(=O)Oc1cc(-c2ccc(C)cc2)cc(-n2nncc2C(C)C)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16667230 1.00
SCHEMBL16667447 0.91
SCHEMBL16667471 0.91 P2RX3 (0.38)
SCHEMBL16667452 0.91
SCHEMBL16667434 0.91 P2RX3 (0.38)
SCHEMBL16667326 0.88 P2RX3 (0.35)
SCHEMBL2272789 0.86
SCHEMBL2275831 0.86
SCHEMBL18036356 0.83 P2RX3 (0.40)
SCHEMBL18036372 0.83 P2RX3 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607356-B1 Triazole-substituted arylamide derivatives and their use as P2x3 and /or P2x2/3 purinergic receptor antagonists HOFFMANN LA ROCHE (CH) 2015-04-29 EP claimed